Active surveillance for prostate cancer: A systematic review of clinicopathologic variables and biomarkers for risk stratification

European Urology

Volumn 67, Issue 4, 2015, Pages 619-626

  Loeb, Stacy ^a   Bruinsma, Sophie M ^b   Nicholson, Joseph ^a   Briganti, Alberto ^c   Pickles, Tom ^d,h   Kakehi, Yoshiyuki ^e   Carlsson, Sigrid V ^f,g   Roobol, Monique J ^b  

^a NEW YORK UNIVERSITY   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e KAGAWA UNIVERSITY   (Japan)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Active surveillance; Genetic markers; Nomogram; Prostate cancer; PSA; Risk stratification; Treatment

Indexed keywords

BIOLOGICAL MARKER; HYBRID PROTEIN; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; TRANSMEMBRANE PROTEASE SERINE 2 V ETS AVIAN ERYTHROBLASTOSIS VIRUS E26 ONCOGENE HOMOLOG GENE FUSION; TUMOR ANTIGEN; UNCLASSIFIED DRUG; PROSTATE CANCER ANTIGEN 3, HUMAN; SERINE PROTEINASE; TMPRSS2 PROTEIN, HUMAN;

ACTIVE SURVEILLANCE; AGE; ARTICLE; ASSESSMENT OF HUMANS; COCHRANE LIBRARY; DISEASE COURSE; DISEASE SURVEILLANCE; EMBASE; FAMILY HISTORY; FOLLOW UP; HEREDITY; HUMAN; MEDLINE; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HEALTH INDEX; RACE; SYSTEMATIC REVIEW; BIOPSY; BLOOD; GENE FUSION; HEALTH SURVEY; MALE; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RISK FACTOR;

ANTIGENS, NEOPLASM; BIOPSY; DISEASE PROGRESSION; HUMANS; MALE; ONCOGENE FUSION; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SERINE ENDOPEPTIDASES;

EID: 84923091818     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.10.010     Document Type: Review

References (68)

1. M.M. Center, A. Jemal, and J. Lortet-Tieulent International variation in prostate cancer incidence and mortality rates Eur Urol 61 2012 1079 1092
2. F.H. Schroder, J. Hugosson, and M.J. Roobol Prostate-cancer mortality at 11 years of follow-up N Engl J Med 366 2012 981 990
3. M.J. Roobol, M. Kerkhof, and F.H. Schroder Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC) Eur Urol 56 2009 584 591
4. L. Klotz Prostate cancer overdiagnosis and overtreatment Curr Opin Endocrinal Diabetes Obes 20 2013 204 209
5. K.S. Tseng, P. Landis, J.I. Epstein, B.J. Trock, and H.B. Carter Risk stratification of men choosing surveillance for low risk prostate cancer J Urol 183 2010 1779 1785
6. K. Lees, M. Durve, and C. Parker Active surveillance in prostate cancer: patient selection and triggers for intervention Curr Opin Urol 22 2012 210 215
7. R.C.N. van den Bergh, H.U. Ahmed, C.H. Bangma, M.R. Cooperberg, A. Villers, and C.C. Parker Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review Eur Urol 65 2014 1023 1031
8. M.R. Abern, M.R. Bassett, and M. Tsivian Race is associated with discontinuation of active surveillance of low-risk prostate cancer: results from the Duke Prostate Center Prostate Cancer Prostatic Dis 16 2013 85 90
9. V. Iremashvili, M.S. Soloway, D.L. Rosenberg, and M. Manoharan Clinical and demographic characteristics associated with prostate cancer progression in patients on active surveillance J Urol 187 2012 1594 1599
10. D. Sundi, O. Kryvenko, and J. Epstein Reclassification rates are higher among African American men than white men on active surveillance J Urol Suppl 191 2014 e598 e599
11. J.A. Cohn, P.P. Dangle, and C.E. Wang The prognostic significance of perineural invasion and race in men considering active surveillance BJU Int 114 2014 75 80
12. J. Cullen, S. Brassell, Y. Chen, S. Srivastava, and D. McLeod All-cause mortality among military health care beneficiaries with prostate cancer undergoing active surveillance J Urol 185 2011 e64
13. N.E. Fleshner, M.S. Lucia, and B. Egerdie Effect of baseline characteristics on relative risk of prostate cancer progression in the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial Eur Urol Suppl 10 2011 51 52
14. A. Smith, M. Coward, and H. Doak Outcomes and implications of follow-up biopsies of men on active surveillance for low-risk prostate cancer J Urol Suppl 181 2009 608
15. M.A. Dall'Era, B.R. Konety, and J.E. Cowan Active surveillance for the management of prostate cancer in a contemporary cohort Cancer 112 2008 2664 2670
16. H.D. Patel, Z. Feng, P. Landis, B.J. Trock, J.I. Epstein, and H.B. Carter Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer J Urol 191 2014 629 637
17. W.V. Shappley III, S.A. Kenfield, and J.L. Kasperzyk Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort J Clin Oncol 27 2009 4980 4985
18. D.W. Lin, L.F. Newcomb, and E.C. Brown Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study Clin Cancer Res 19 2013 2442 2450
19. M. Bul, X. Zhu, and R. Valdagni Active surveillance for low-risk prostate cancer worldwide: the PRIAS study Eur Urol 63 2013 597 603
20. L. Klotz, L.Y. Zhang, A. Lam, R. Nam, A. Mamedov, and A. Loblaw Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer J Clin Oncol 28 2010 126 131
21. I. Sternberg, C. Yu, and G. Paz Predicting progression in patients followed with active surveillance for low-risk prostate cancer [abstract 38] J Clin Oncol 32 Suppl 4 2014
22. J.M. Whitson, S.P. Porten, and J.F. Hilton The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer J Urol 185 2011 1656 1660
23. L.Y. Zhang, A. Loblaw, and L. Klotz Modeling prostate specific antigen kinetics in patients on active surveillance J Urol 176 2006 1392 1397
24. K.D. Berg, B. Vainer, and F.B. Thomsen ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer Eur Urol 66 2014 851 860
25. M. Bul, R.C.N. van den Bergh, and A. Rannikko Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program Eur Urol 61 2012 370 377
26. K.C. Cary, J.E. Cowan, and M. Sanford Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies Eur Urol 66 2014 337 342
27. S.E. Eggener, A. Mueller, and R.K. Berglund A multi-institutional evaluation of active surveillance for low risk prostate cancer J Urol 181 2009 1635 1641 discussion 1641
28. H. Hirama, M. Sugimoto, K. Ito, T. Shiraishi, and Y. Kakehi The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort J Cancer Res Clin Oncol 140 2014 257 263
29. L. Klotz Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer J Urol 172 2004 S48 S50 discussion S51
30. D.V. Makarov, S. Isharwal, and L.J. Sokoll Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer Clin Cancer Res 15 2009 7316 7321
31. M.S. Soloway, C.T. Soloway, S. Williams, R. Ayyathurai, B. Kava, and M. Manoharan Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience BJU Int 101 2008 165 169
32. R. Venkitaraman, A. Norman, and R. Woode-Amissah Predictors of histological disease progression in untreated, localized prostate cancer J Urol 178 2007 833 837
33. J.N. Cornu, G. Cancel-Tassin, C. Egrot, C. Gaffory, F. Haab, and O. Cussenot Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer Prostate 73 2013 242 249
34. S. Isharwal, D.V. Makarov, and H.B. Carter DNA content in the diagnostic biopsy for benign-adjacent and cancer-tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management programme BJU Int 105 2010 329 333
35. R.C.N. van den Bergh, H. Vasarainen, and H.G. van der Poel Short-term outcomes of the prospective multicentre "Prostate Cancer Research International: Active Surveillance" study BJU Int 105 2010 956 962
36. I.F. San Francisco, L. Werner, M.M. Regan, M.B. Garnick, G. Bubley, and W.C. DeWolf Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance J Urol 185 2011 471 476
37. A. Valeri, G. Papin, and M.P. Moineau Is screen-detected prostate cancer in high risk families eligible for active surveillance? Eur Urol Suppl 9 2010 196
38. A.J. Burton, R.M. Martin, and J.L. Donovan Associations of lifestyle factors and anthropometric measures with repeat PSA levels during active surveillance/monitoring Cancer Epidemiol Biomarkers Prev 21 2012 1877 1885
39. C.L. Goh, E.J. Saunders, and D.A. Leongamornlert Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohort BJU Int 112 2013 666 673
40. G.M. Mukerji, J. Nariculam, G.O. Hellawell, P. Abel, and M. Winkler Outcome of patients on active surveillance for low-risk prostate cancer in a cohort of British men with low screening penetrance BJU Int Suppl 106 2010 3
41. R.C. van den Bergh, S. Roemeling, and M.J. Roobol Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men BJU Int 103 2009 1472 1477
42. R. Venkitaraman, A. Norman, and R. Woode-Amissah Prostate-specific antigen velocity in untreated, localized prostate cancer BJU Int 101 2008 161 164
43. S. Jhavar, J. Bartlett, and G. Kovacs Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance Prostate Cancer Prostatic Dis 12 2009 143 147
44. N.J. van As, A.R. Norman, and K. Thomas Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance Eur Urol 54 2008 1297 1305
45. V. Iremashvili, J. Burdick-Will, and M.S. Soloway Improving risk stratification in patients with prostate cancer managed by active surveillance: a nomogram predicting the risk of biopsy progression BJU Int 112 2013 39 44
46. V. Iremashvili, M. Manoharan, D.L. Rosenberg, and M.S. Soloway Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models BJU Int 111 2013 574 579
47. M.K. Ng, N. Van As, and K. Thomas Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time BJU Int 103 2009 872 876
48. A. Adamy, D.S. Yee, and K. Matsushita Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer J Urol 185 2011 477 482
49. D.S. Yee, A. Adamy, and R. Pinochet The rate of upgrading and upstaging on immediate repeat biopsy in patients eligible for active surveillance is not related to extent of first biopsy J Urol 183 2010 e57
50. G. Fromont, J. Irani, and A. Ruffion Interest of early confirmatory biopsies and centralized pathological review to select prostate cancer patients for active surveillance Eur Urol Suppl 10 2011 315
51. M.S. Soloway, C.T. Soloway, A. Eldefrawy, K. Acosta, B. Kava, and M. Manoharan Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment Eur Urol 58 2010 831 835
52. M.H. Umbehr, E.A. Platz, and S.B. Peskoe Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density BJU Int 113 2014 561 567
53. G.A. Barayan, F. Brimo, and L.R. Begin Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort BJU Int 114 2014 E99 E104
54. C. Welty, J. Cowan, and H. Nguyen Factors associated with biopsy progression on active surveillance [abstract 19] J Clin Oncol 32 Suppl 4 2014
55. J.J. Tosoian, S. Loeb, and Z. Feng Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer J Urol 188 2012 1131 1136
56. M. Komisarenko, L.M. Wong, and P. Richard Patients that demonstrate Gleason 6 volume progression on active surveillance have a substantially greater risk of grade progression on further follow-up J Urol 191 2014 e720
57. A. Loblaw, L. Zhang, and A. Lam Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance J Urol 184 2010 1942 1946
58. Y. Kakehi, T. Kamoto, and T. Shiraishi Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer Jpn J Clin Oncol 38 2008 122 128
59. A.E. Ross, S. Loeb, and P. Landis Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program J Clin Oncol 28 2010 2810 2816
60. A. Khatami, G. Aus, J.E. Damber, H. Lilja, P. Lodding, and J. Hugosson PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section Int J Cancer 120 2007 170 174
61. V. Iremashvili, M. Manoharan, S.D. Lokeshwar, D.L. Rosenberg, D. Pan, and M.S. Soloway Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients BJU Int 111 2013 396 403
62. Y. Krakowsky, A. Loblaw, and L. Klotz Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics J Urol 184 2010 131 135
63. A.C. Pujara, A.J. Stephenson, R. Miocinovic, R.K. Berglund, and J.S. Jones Prostate-specific antigen rises faster in patients with multiple negative biopsies compared to patients followed by active surveillance for low-risk prostate cancer J Urol 183 Suppl 4 2010 e831
64. A. Vickers Statistical considerations for patient selection and triggers for intervention in active surveillance L. Kotz, Active surveillance for localized prostate cancer: a new paradigm for clinical management 2012 Humana Press New York, NY
65. S. Loeb, M. Han, K.A. Roehl, J.A. Antenor, and W.J. Catalona Accuracy of prostate weight estimation by digital rectal examination versus transrectal ultrasonography J Urol 173 2005 63 65
66. J.J. Tosoian, S. Loeb, and A. Kettermann Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program J Urol 183 2010 534 538
67. R. Venkitaraman, K. Thomas, and P. Grace Baseline urinary phytoestrogen levels and the natural history of untreated, localised prostate cancer in a British population Int J Biol Markers 23 2008 192 197
68. S.P. Porten, J.M. Whitson, and J.E. Cowan Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance J Clin Oncol 29 2011 2795 2800